Cambridge startup lands $25M round for genetic sequencing play

Cambridge, MA-based Foundation Medicine has raised $25 million in a Series A, coming out of stealth mode with bold plans to create clinical lab tests that can use the latest in genetic sequencing technology to identify personalized cancer therapies for patients. As expected, Alexis Borisy, who landed as an entrepreneur-in-residence with Third Rock Ventures after getting bounced from CombinatoRx last year, was named as the new CEO. Third Rock led the round. "Over the past decade, cancer genome...